Pathology & Laboratory Medicine

Warning message

Selective filter "Related Faculty (field_biblio_faculty) (selective)" has limited the amount of total results. Please, review you query configuration.

Publications

Filter By Faculty

Filter by Principal Investigator

2023

Yeshoua B, Bowman C, Dullea J, Ditkowsky J, Shyu M, Lam H, et al. Interventions to reduce repetitive ordering of low-value inpatient laboratory tests: a systematic review. BMJ Open Qual. 2023;12(1).

Liu W, Newhall KP, Khani F, Barlow LM, Nguyen D, Gu L, et al. The Cytidine Deaminase APOBEC3G Contributes to Cancer Mutagenesis and Clonal Evolution in Bladder Cancer. Cancer Res. 2023;83(4):506-520.

Mesa KR, O'Connor KA, Ng C, Salvatore SP, Littman DR. Niche-specific macrophage loss promotes skin capillary aging. bioRxiv. 2023.

Gould CV, Free RJ, Bhatnagar J, Soto RA, Royer TL, Maley WR, et al. Transmission of yellow fever vaccine virus through blood transfusion and organ transplantation in the USA in 2021: report of an investigation. Lancet Microbe. 2023;4(9):e711-e721.

Sud K, Narula N, Aikawa E, Arbustini E, Pibarot P, Merlini G, et al. The contribution of amyloid deposition in the aortic valve to calcification and aortic stenosis. Nat Rev Cardiol. 2023;20(6):418-428.

Liu A, Kremyanskaya M, Mehrazin R, Si Q, Robinson BD, Cushing MM, et al. Erythropoietin-secreting metanephric adenoma presenting as erythrocytosis. Am J Hematol. 2023;98(11):1808-1813.

Velu PD, Sipley J, Marino J, Ghanshani S, Lukose G, Cong L, et al. Evaluation of a Zoonotic Orthopoxvirus PCR Assay for the Detection of Mpox Virus Infection. J Mol Diagn. 2023;25(10):740-747.

Callum J, Bégin P, Jamula E, Liu Y, Kron AT, Auclair M-, et al. Lessons learned from the CONCOR-1 trial. Transfus Med. 2023;33(1):21-25.

Rogerson D, Alkelai A, Giordano J, Pantrangi M, Hsiao M-, Nhan-Chang C-, et al. Investigation into the genetics of fetal congenital lymphatic anomalies. Prenat Diagn. 2023;43(6):703-716.

Nuzzo PV, Ravera F, Saieva C, Zanardi E, Fotia G, Malgeri A, et al. Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer. Ther Adv Med Oncol. 2023;15:17588359231156147.